Core Viewpoint - The Shenzhen National Biopharmaceutical Base (Pingshan) has been recognized as one of the top four biomanufacturing innovation bases in China, reflecting its significant progress in the biopharmaceutical industry over the past two decades [1][4]. Group 1: Industry Recognition and Growth - The Pingshan biopharmaceutical industry has been acknowledged for its innovation and development, evidenced by its inclusion in the "2025 Most Innovative Biomanufacturing Base" list [1][4]. - An international delegation from the U.S. praised Pingshan's complete industrial ecosystem during their visit, highlighting the area's advancements in biopharmaceutical technologies [3][4]. - Pingshan has established itself as a leading hub for biopharmaceuticals in Shenzhen, with a growing consensus among industry players that it is the preferred location for biopharmaceutical enterprises [4][6]. Group 2: Industry Infrastructure and Ecosystem - Pingshan has concentrated its efforts on strategic emerging industries, particularly biopharmaceuticals and high-end medical devices, with 1,290 biopharmaceutical companies currently operating in the area [6][7]. - The biopharmaceutical sector in Pingshan is projected to generate an output value of 26.78 billion yuan in 2024, maintaining its leading position in Shenzhen [6]. - The region has developed a robust industrial ecosystem, featuring major companies like Fosun Pharma and Sanofi Pasteur, alongside numerous innovative small and medium enterprises [6][7]. Group 3: Supportive Policies and Services - Pingshan has implemented a comprehensive service system for the biopharmaceutical industry, providing over 2.5 million square meters of high-standard industrial space for companies [9][10]. - The district has introduced financial support policies, including a biopharmaceutical and innovative drug special policy, and established a fund cluster exceeding 5 billion yuan to support innovation [10][12]. - A three-tiered service mechanism has been created to enhance efficiency in administrative processes, significantly reducing response times for companies [10][12]. Group 4: Future Development and Vision - Pingshan aims to continue its role as a leading biopharmaceutical innovation hub by leveraging its national base status and focusing on research, innovation, and industrial clustering [11][12]. - The area is expected to attract more global industry leaders and innovative projects, further solidifying its position in the global biopharmaceutical landscape [11][12].

Core Insights - The 17th China Bio-Industry Conference was held on September 4, 2025, in Wuhan, showcasing the latest innovations in the bio-manufacturing sector [1][3] - The conference highlighted the achievements of Wuhan's Optics Valley Bio-City, which has become a leading hub for biopharmaceuticals in China, housing over 4,200 companies and nurturing 531 high-tech enterprises [3][6] Group 1: Event Highlights - The conference released the "Most Innovative Bio-Manufacturing Base" list, recognizing ten national bio-industry bases, including Wuhan, Shanghai, Beijing, Hangzhou, and Shenzhen [1] - Five companies from Wuhan, including He Yuan Bio, Aibotai, and Youzhiyou, were ranked among the top 20 most innovative enterprises from hundreds of projects across 23 national bio-industry bases [1] Group 2: Achievements in Bio-Medicine - In the first half of the year, Optics Valley Bio-City approved 14 new class I innovative drugs for clinical trials, the highest number in three years, and 28 class III medical devices, matching last year's total [4] - The city is currently developing over 400 class I new drugs, accounting for 90% of the province's total, and has certified over 307 class III medical devices, representing 70% of the province's total [4] Group 3: Notable Exhibits - Major companies from Optics Valley Bio-City showcased groundbreaking products at the conference, including the world's first 5.0T whole-body MRI system and a novel "rice-derived" recombinant human albumin injection [4] - Binhui Bio's OH2 injection, the first oncolytic virus drug using type II herpes simplex virus as a carrier, is undergoing critical clinical research and has received national support for major new drug development [4]